HRTS
GLP-1, Obesity & Cardiometabolic ETF

Invest in Obesity and Diabetes innovation including GLP-1 Weight Loss Treatments

LEARN MORE

Share Price:

$29.53

March 10, 2025

Factsheet

How to Invest

Why Invest in HRTS ETF?

Disruptive Innovation

GLP-1 therapies are a breakthrough obesity and diabetes treatment, and may in future treat Alzheimer's, Parkinson's and other conditions.

Long-term Growth

Only 3% of the 1 billion people affected by obesity are treated today, forecast to grow to 2 billion obese people by 2030.

Source: Novo Nordisk, World Obesity Atlas

Healthcare Expertise

Managed by 25-year veteran healthcare investor Dr. Song, MD, PhD, CFA, advised by Dr. Jens Juul Holst, the GLP-1 pioneer.

Fund Overview

Fund Details

As of March 10, 2025

Primary Exchange

Nasdaq

Ticker

HRTS

AuM ($M)

$62,322,288

# of Holdings

Fund Inception Date

11/20/23

Gross Expense Ratio

0.99%

Net Expense Ratio*

0.75%

Implied Liquidity (USD)

$61M

Shares Outstanding

2,100,000

Portfolio Manager

David K. Song, MD, PhD, CFA

Investment Advisor

Tema ETFs LLC

Investment Sub-Advisor

NEOS Investments, LLC

*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.

Fund Summary

The actively managed Tema GLP-1, Obesity & Cardiometabolic ETF seeks to provide long-term growth of capital by investing in GLP-1 and weight loss companies leading the fight against obesity and cardiometabolic diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools.  The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.

Investment Case

Summary Prospectus

Introducing HRTS

Portfolio Breakdown

Top 10 holdings

As of March 10, 2025

Company

% of Nav

ELI LILLY & CO.

10.06%

UNITEDHEALTH GROUP, INC.

5.51%

NOVO NORDISK A/S

4.53%

ASTRAZENECA PLC

4.27%

ROCHE HOLDING AG

3.98%

ABBOTT LABORATORIES

3.94%

VERTEX PHARMACEUTICALS, INC.

3.92%

BRIDGEBIO PHARMA, INC.

3.72%

CHUGAI PHARMACEUTICAL CO., LTD.

3.23%

THERMO FISHER SCIENTIFIC, INC.

3.20%

Download Holdings

Country Breakdown

United States

73.25%

Denmark

7.34%

Switzerland

6.87%

United Kingdom

5.55%

Others

6.99%

Industry Breakdown

Healthcare

99.38%

Cash & Cash Equivalents

0.64%

Performance
Distributions
Premium / Discount

Prices & Performance

As of

Feb 28, 2025

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

NAV

-3.55% -12.41%

-7.20% -3.60%

14.06% 9.87%

Market Price

-3.84% -12.76%

-7.62% -4.24%

13.92% 9.60%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

LT Cap Gains

Dec 11, 2024

Dec 12, 2024

$0.46931283

$0.14290283

$0.32641

$0.00

-0.5 -0.17 -0.17 -0.27 -0.17 -0.19 0.48 0.33 0.51 0.36 0.41 -0.09 0.41 0.43 0.47 0.28 0.58 0.36 0.55 -0.08

Premium/Discount

Сhart Table

HRTS NAV / Market Price

NAV$29.68

NAV change (1D)($0.66)

Median Bid/Ask Spread (30 Day)0.3%

Market Price$29.53

Market Price Change (1D)($0.75)

Premium/Discount-0.5%

As of: March 10, 2025

March-25 February-25 January-25 December-24 November-24 October-24 September-24 August-24 July-24 June-24 May-24 April-24 March-24

How does the Tema HRTS ETF fit in a portfolio?

Investment Style Box

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM

HRTS ETF

Equity core

Where could a position be funded from?

Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
Provides a balanced exposure across key technologies and company risk profiles.
Could replace a satellite or a growth-oriented position.

How to buy

*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.

Risk Information

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing.

On 07/01/2024 the Tema Obesity & Cardiometabolic ETF was renamed Tema GLP-1, Obesity & Cardiometabolic ETF. Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable.

Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.

Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Funds evaluate ESG factors to assess and exclude certain investments for non-financial reasons, the Funds may forego some market opportunities available to funds that do not use these ESG factors.

Tema ETFs LLC serves as the investment adviser to Tema GLP-1, Obesity & Cardiometabolic ETF (the “Fund”), and NEOS Investments, LLC serves as a sub adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.

Get in Touch

HRTS GLP-1, Obesity & Cardiometabolic ETF

$29.53

Why Invest in HRTS ETF?

Disruptive Innovation

Long-term Growth

Healthcare Expertise

Fund Overview

Fund Details

As of March 10, 2025

Fund Summary

Introducing HRTS

Portfolio Breakdown

Top 10 holdings

As of March 10, 2025

Country Breakdown

United States

Denmark

Switzerland

United Kingdom

Others

Industry Breakdown

Healthcare

Cash & Cash Equivalents

Prices & Performance

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

ST Cap Gains

LT Cap Gains

Premium/Discount

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

HRTS NAV / Market Price

How does the Tema HRTS ETF fit in a portfolio?

Investment Style Box

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

Where could a position be funded from?

Fund Documents

How to buy

Explore our ETFs

HRTS

TOLL

CANC

LUX

MNTL

RSHO

VOLT

Risk Information

Growth

Quality

Core

Alternatives

Funds Resources

HRTS
GLP-1, Obesity & Cardiometabolic ETF